Zhejiang Hisun Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

From its origins as a chemical works in 1956 to becoming a Shanghai-listed pharmaceutical powerhouse in 2000, Zhejiang Hisun Pharmaceutical has steadily scaled into a global player-forming a 2012 JV with Pfizer, winning special recognition during the 2020 COVID response, launching its first innovative drug Habermeb in 2021, and moving into Nutrition & Health Ingredients in 2024-backed by a state-affiliated anchor owner, Zhejiang Haizheng Group, holding 27.45% of shares and leadership under CEO/Chairman Weihong Xiao; today Hisun operates three business groups (chemical medicine, biological medicine, big health) with R&D centers in Taizhou, Shanghai, Hangzhou and the U.S., a team of over 100 R&D professionals, more than 80 international first-class production lines, exports APIs to over 70 countries (with 80% of API income from overseas), drug formulations prescribed in nearly 10,000 hospitals, and a product mix spanning anti-tumor to cardiovascular therapies-financially reporting CN¥9.79 billion revenue and CN¥601.2 million net income in 2024, a CNY 96.46 million share repurchase in 2024, a CNY 0.21 per-share cash dividend for 2025, and a market capitalization of approximately $2 billion as of July 24, 2025, while holding over 1,100 patent applications (more than 500 authorized) and pursuing ADCs, biosimilars and other advanced assets to drive future growth.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS): Intro

• Founded: 1956 (originated as a chemical enterprise; moved into pharmaceuticals in the early 1970s)
• Stock listing: Shanghai Stock Exchange (600267.SS), listed in 2000 - state-owned listed entity
• Key JV: Hisun-Pfizer Pharmaceutical Co., Ltd., established 2012 (collaboration on development and commercialization)
• COVID-19 recognition: 2020 - honored by the Joint Prevention and Control Team of the State Council for epidemic efforts
• First in-house innovative drug: Habermeb Tablet approved and listed in 2021
• Business expansion: 2024 - launched operations in Nutrition and Health Ingredients leveraging advanced tech

• API manufacturing and sales - large-scale synthesis and contract manufacturing for domestic and export markets (antibiotics, cardiovascular, CNS, etc.).
• Formulated generics - branded and unbranded finished-dosage forms sold through hospitals, distributors and retail pharmacies.
• Innovative drugs - commercialization and licensing of internally developed molecules (e.g., Habermeb) and milestone/license deals via partnerships.
• Joint ventures and partnerships - technology transfer, co-development and co-commercialization (notably with Pfizer in 2012) to access new products and markets.
• Nutrition & Health Ingredients - ingredient development, contract supply and finished-product solutions targeting functional foods and supplements (launched 2024).

• Upstream: chemical synthesis and API production at multi-site manufacturing campuses with GMP compliance for domestic and export markets.
• Midstream: formulation R&D and large-scale drug product manufacturing for hospital and retail channels.
• Downstream: sales, distribution and marketing across domestic hospital procurement, pharmacy chains and international exports; licensing revenue from collaborations.
• Supporting functions: centralized R&D centers, quality control labs, regulatory affairs and supply-chain integration to ensure product traceability and compliance.

• Transition from generics to innovation: first approved proprietary drug (Habermeb) in 2021 demonstrates strategic shift.
• Pipeline strategy: incremental improvements to existing molecules, novel formulations, and selective in-licensing/partnered programs (e.g., JV with Pfizer).
• Investment profile: sustained R&D spend to move higher up the value chain and support Nutrition & Health Ingredients platform launched in 2024.

• Regulatory risk: approvals, GMP inspections and pricing reforms in China can affect margins and market access.
• Competition: intense pricing pressure in generics and global API commoditization.
• Supply-chain & raw material volatility: feedstock price swings and logistics can impact cost of goods sold and margins.
• R&D execution: successful commercialization of innovative drugs requires sustained investment and regulatory success.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS): History

• Major state-affiliated ownership: Zhejiang Haizheng Group Co., Ltd. held a 27.45% stake as of December 30, 2024.
• Executive leadership: Weihong Xiao serves as both CEO and Chairman, consolidating strategic and operational control.
• Board and management: Senior executives on the board include Du Jiaqiu (Senior Vice President) and Jiang Ling (Senior Vice President & CFO), linking management and oversight.
• Shareholder returns in 2024: cash dividend of CNY 0.21 per share declared (payable May 16, 2025) and a share repurchase program totaling CNY 96.46 million executed during 2024.
• Institutional interest: as of May 30, 2025, 18 institutional owners held a combined 3,725,564 shares.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS): Ownership Structure

• Mission: 'Perseverance in drug innovation, achieving the dream of health and longevity.'
• Core values: Honesty, Innovation, Collaboration & Diligence - embedded across governance, quality systems and partner selection.
• Quality & compliance: Operates under a stringent pharmaceutical-grade quality system aligned with international GMP standards.
• R&D capacity: Maintains a focused R&D team of over 100 professionals and engages in strategic cooperation with leading academic institutions to accelerate drug discovery and development.
• Global footprint: Sales network covering Africa, Asia, Australia, Central/South America, Eastern Europe, the Middle East, North America and Western Europe.

• Business model: Combines in-house chemical and biologic drug development, contract manufacturing, and an international commercial pipeline for generics and specialty medicines.
• Value drivers: R&D productivity, regulatory approvals (domestic and overseas), manufacturing scale and global distribution partnerships.
• Revenue mix: Domestic prescription drugs, export generics, contract manufacturing and licensing income.

• How it earns money: Sells finished pharmaceuticals and APIs, offers CDMO/CMO services, licenses products/technology and grows recurring sales via chronic-therapy generics and specialty portfolios.
• Investment focus: Sustained R&D spend, scaling manufacturing capacity, and expanding regulated-market approvals to improve margin profile and diversify geographic revenue.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS): Mission and Values

• Three business groups: Chemical Medicine, Biological Medicine, Big Health - enabling diversified revenue streams and risk mitigation.
• R&D network: research centers in Taizhou, Shanghai, Hangzhou and the U.S., supporting early discovery, process development, and global regulatory alignment.
• Manufacturing footprint: more than 80 international first‑class production lines for pharmaceutical preparations, covering APIs and formulations compliant with major regulatory standards.

• API production and export: supplies active pharmaceutical ingredients to over 70 countries and regions; ~80% of API revenue is generated from overseas markets, reflecting strong global penetration.
• Formulations and domestic reach: finished drugs are distributed nationwide in China and prescribed in nearly 10,000 hospitals, underpinning stable domestic sales channels.
• End‑to‑end development: undertakes discovery, process optimization, clinical development, and scale‑up - more than 50 special projects for the creation and manufacture of major new drugs demonstrate sustained innovation investment.
• Regulatory & quality systems: multi‑site QC/QA and international GMP compliance to support exports and cross‑border registrations.

• Listed entity: publicly traded on the Shanghai Stock Exchange (600267.SS) with a mix of institutional and retail investors.
• Major shareholder structure: controlled primarily by entities within the Hisun Group/holding family of companies (group-level shareholdings and affiliated entities hold the largest blocks), with additional stakes held by mainland institutional investors and public float for market liquidity.
• Governance emphasis: board‑level focus on R&D strategy, international expansion, and compliance to support global supply contracts and hospital procurement partnerships.

• API exports - high-margin, global contracts with pharmaceutical manufacturers and generics producers; foreign currency exposure helps diversify domestic market cyclicality.
• Formulations sales - steady domestic prescription demand via hospital procurement, chronic disease portfolios, and branded generics.
• Biologics pipeline - higher ASP (average selling price) potential and longer product life cycles; strategic move to capture premium segment revenues.
• Big‑health segment - consumer health, nutraceuticals, and chronic disease support products that provide recurring, lower‑regulatory‑risk cash flows.

• Integrated value chain: API → formulation → distribution reduces margin leakage and secures supply continuity.
• Scale and quality: extensive production lines and international GMP alignment enable competitive cost structure and export access.
• R&D footprint: multi‑site research centers (Taizhou, Shanghai, Hangzhou, U.S.) accelerate product development and global registration strategies.
• Global customer base: diversified export markets minimize single‑market dependency.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS): How It Works

• Core revenue sources: sale of APIs (active pharmaceutical ingredients), finished dosage forms, biologics, and contract manufacturing/CRO services.
• Geographic mix: strong export orientation for APIs (overseas markets account for ~80% of API income) and domestic focus for formulations-medicines prescribed in nearly 10,000 hospitals across China.
• Therapeutic coverage: anti-tumor, anti-infection, cardiovascular, endocrine, immunosuppression, antidepressant, liver care, and orthopaedics.

• R&D-driven launches: development of generics and biosimilars to capture volume and margin in selected therapeutic areas.
• API scale economics: large-volume API production for export markets, leveraging lower-cost manufacturing and international regulatory approvals.
• Formulation sales & hospital procurement: distribution to hospitals and pharmacies, amplified by inclusion in national centralized procurement lists for more than 10 medicines.
• International partnerships and regulatory approvals: access to over 70 export markets for APIs, enabling foreign-currency revenue streams and diversification.

• Publicly listed on the Shanghai Stock Exchange (600267.SS) with a mix of institutional and retail shareholders.
• Management focus on transitioning from cyclical API margins to higher-value biologics and finished dosage forms while maintaining export scale.

• Manufacturing: multiple production bases for APIs and formulations to optimize cost and regulatory compliance.
• R&D: pipeline programs across oncology, anti-infectives and immunology; investments targeted at biosimilars and differentiated generics.
• Commercial: domestic sales forces and hospital distribution networks plus international sales teams/agents for API exports.

• Volume-driven export margins from API sales to >70 countries, with currency diversification benefits.
• Price and volume gains via national centralized procurement listings, improving uptake in public hospitals and reducing patient cost.
• Product mix shift toward higher-margin formulations and biologics to improve profitability after the 2023 loss and 2024 turnaround.

Zhejiang Hisun Pharmaceutical Co., Ltd. (600267.SS): How It Makes Money

• Market capitalization: $2.0 billion (as of July 24, 2025).
• Net income: CN¥601.2 million (2024), reflecting a recovery and improved margins.
• Strategic diversification: entered the Nutrition & Health Ingredients industry in 2024 to broaden revenue streams.
• Innovation: >1,100 patent applications and >500 authorized patents, reinforcing product differentiation and licensing potential.
• R&D focus: chemical and biological drug platforms (including ADCs and biosimilars) to capture higher-value markets.

• API manufacturing and low-cost scale production of small-molecule drugs - steady, high-volume cash flow and export revenue.
• Finished-dose generics and specialty therapeutics - domestic hospital and retail sales, tenders, and institutional supply.
• Biologics and biosimilars - higher-margin growth area driven by R&D and in-house biologics capabilities.
• Antibody Drug Conjugates (ADCs) development - pipeline value and future licensing/partnering opportunities.
• Nutrition & Health Ingredients - new product lines and cross-selling into existing distribution channels since 2024.
• Contract development and manufacturing (CDMO) and licensing - fee-based revenue plus milestone and royalty upside.

• Export growth via global sales network - expanding presence in emerging markets and contract supply agreements.
• Pipeline commercialization - transitioning high-value biologics and ADC candidates to clinical/commercial stages.
• Patent-backed product protection and licensing - monetization through royalties and partnerships.
• Nutrition & Health Ingredients launch - diversifies margins and reduces dependence on traditional generics pricing pressures.

• Listed on the Shanghai Stock Exchange (600267.SS) with a mix of institutional, retail and strategic shareholders; management-aligned governance supporting long-term R&D investment.
• Stated mission and values emphasize innovation, patient-focused therapeutics and global access - see: Mission Statement, Vision, & Core Values (2026) of Zhejiang Hisun Pharmaceutical Co., Ltd.